JNJ-40411813
≥99%
- Product Code: 101101
CAS:
1127498-03-6
| Molecular Weight: | 344.88 g./mol | Molecular Formula: | C₂₀H₂₅ClN₂O |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | 2-8℃ |
Product Description:
JNJ-40411813 is primarily investigated for its potential therapeutic applications in the field of neuroscience, particularly in the treatment of psychiatric and neurological disorders. It functions as a negative allosteric modulator of the metabotropic glutamate receptor 2 (mGluR2), which plays a significant role in regulating neurotransmitter release and synaptic plasticity. By modulating this receptor, it is being studied for its efficacy in addressing conditions such as schizophrenia, anxiety, and depression. Early research suggests that it may help in reducing symptoms associated with these disorders by altering glutamate signaling pathways, which are often dysregulated in such conditions. Additionally, its unique mechanism of action offers a promising alternative to traditional treatments, potentially minimizing side effects and improving patient outcomes. Ongoing clinical trials aim to further explore its safety, tolerability, and effectiveness in diverse patient populations.
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.001 | 10-20 days | ฿18,468.00 |
+
-
|
| 0.005 | 10-20 days | ฿51,300.00 |
+
-
|
JNJ-40411813
JNJ-40411813 is primarily investigated for its potential therapeutic applications in the field of neuroscience, particularly in the treatment of psychiatric and neurological disorders. It functions as a negative allosteric modulator of the metabotropic glutamate receptor 2 (mGluR2), which plays a significant role in regulating neurotransmitter release and synaptic plasticity. By modulating this receptor, it is being studied for its efficacy in addressing conditions such as schizophrenia, anxiety, and depression. Early research suggests that it may help in reducing symptoms associated with these disorders by altering glutamate signaling pathways, which are often dysregulated in such conditions. Additionally, its unique mechanism of action offers a promising alternative to traditional treatments, potentially minimizing side effects and improving patient outcomes. Ongoing clinical trials aim to further explore its safety, tolerability, and effectiveness in diverse patient populations.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :